Pharmchem Stock Probability Of Bankruptcy
| PCHM Stock | USD 3.05 0.00 0.00% |
PharmChem |
PharmChem Company odds of distress Analysis
PharmChem's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current PharmChem Probability Of Bankruptcy | Less than 40% |
Most of PharmChem's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PharmChem is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of PharmChem probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting PharmChem odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of PharmChem financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, PharmChem has a Probability Of Bankruptcy of 40.0%. This is 7.6% lower than that of the Health Care Providers & Services sector and 2.06% lower than that of the Health Care industry. This indicator is about the same for all United States stocks average (which is currently at 39.83).
PharmChem Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PharmChem's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PharmChem could also be used in its relative valuation, which is a method of valuing PharmChem by comparing valuation metrics of similar companies.PharmChem is currently under evaluation in probability of bankruptcy category among its peers.
PharmChem Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.0537 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | (0.06) % | |||
| Current Valuation | 17.56 K | |||
| Price To Earning | (2.30) X | |||
| Price To Book | 0 X | |||
| Price To Sales | 0.0006 X | |||
| Revenue | 26.45 M | |||
| Gross Profit | 5.86 M | |||
| Net Income | (2.15 M) | |||
| Cash And Equivalents | 626 K | |||
| Cash Per Share | 0.11 X | |||
| Debt To Equity | 0.37 % | |||
| Current Ratio | 0.69 X | |||
| Book Value Per Share | 1.30 X | |||
| Earnings Per Share | (0.35) X | |||
| Number Of Employees | 11 | |||
| Beta | 1.15 | |||
| Market Capitalization | 17.55 K | |||
| Total Asset | 16.66 M | |||
| Retained Earnings | (10.28 M) | |||
| Working Capital | 1.28 M | |||
| Current Asset | 6.8 M | |||
| Current Liabilities | 5.52 M | |||
| Z Score | 1.0 | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 4.60 % | |||
| Net Asset | 16.66 M |
About PharmChem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PharmChem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PharmChem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PharmChem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in PharmChem Pink Sheet
PharmChem financial ratios help investors to determine whether PharmChem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PharmChem with respect to the benefits of owning PharmChem security.